Kathryn DiMarco - 31 Mar 2025 Form 4 Insider Report for Organon & Co. (OGN)

Role
Corporate Controller
Signature
/s/ Tarnetta V. Jones, as Attorney-in-Fact for Kathryn DiMarco
Issuer symbol
OGN
Transactions as of
31 Mar 2025
Net transactions value
-$116,486
Form type
4
Filing time
02 Apr 2025, 17:35:12 UTC
Previous filing
05 Sep 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OGN Common Stock Options Exercise $0 +10,638 +46% $0.000000 33,971 31 Mar 2025 Direct
transaction OGN Common Stock Tax liability $52,874 -3,644 -11% $14.51 30,327 31 Mar 2025 Direct F1
transaction OGN Common Stock Options Exercise $0 +8,503 +28% $0.000000 38,830 31 Mar 2025 Direct
transaction OGN Common Stock Tax liability $42,268 -2,913 -7.5% $14.51 35,917 31 Mar 2025 Direct F1
transaction OGN Common Stock Options Exercise $0 +4,294 +12% $0.000000 40,211 31 Mar 2025 Direct
transaction OGN Common Stock Tax liability $21,344 -1,471 -3.7% $14.51 38,740 31 Mar 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OGN Restricted Stock Units Award $0 +40,295 $0.000000 40,295 31 Mar 2025 Common Stock 40,295 Direct F2, F3
transaction OGN Restricted Stock Units Options Exercise $0 -10,638 -33% $0.000000 21,276 31 Mar 2025 Common Stock 10,638 Direct F2, F4
transaction OGN Restricted Stock Units Options Exercise $0 -8,503 -50% $0.000000 8,504 31 Mar 2025 Common Stock 8,503 Direct F2, F5
transaction OGN Restricted Stock Units Options Exercise $0 -4,294 -100% $0.000000 0 31 Mar 2025 Common Stock 4,294 Direct F2, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.
F2 Each RSU converts into one share of Organon common stock.
F3 The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028.
F4 On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day.
F5 On March 31, 2023, RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026.
F6 On March 31, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested.